[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [marketticker...] --------------------------------------------------------------- Sponsor Message [Copper Exploration Heating Up]( [Discover the Opportunities in the New Copper Hotspot]([aff_i?offer_...] --------------------------------------------------------------- November 17, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [Huge Upside Potential With "Staggering" Solar Demand]( [bf8c887b-c2f...](Global solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth. [See How Investors Could Benefit]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [4D Molecular Therapeutics, FDMT]( Recent Analyst Action: Unknown Analyst, analyst at Goldman Sachs, reiterates coverage on [4D Molecular Therapeutics (FDMT)](in the Healthcare sector with a Buy rating and a price target of $68.00 (1 day ago). - Recent Price: $22.5 - Average Analyst Price Target: $38.25 (70.00%) - Market Cap: $680.56M [TipRanks.com]( also reports that [4D Molecular Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $38.25. The target pricing ranges from a high forecast of $68.00 down to a low forecast of $15.00. [4D Molecular Therapeutics (FDMT)](’s last closing price was $22.5 which would put the average price target at $38.25. Here are 3rd party ratings for [FDMT](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 32% (81 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [These 2 Dividend Stocks Pay Every Week]( [bc82e8e3-d6f...](Are you still looking for consistent income in this near-zero interest rate environment? There is a better way. I just revealed the Holy Grail of dividend stocks - a safe, reliable and consistent stock that [pays dividends EVERY single week](- 52 times a year. It's simple: Buy the stock this Monday and you'll get your first dividend payout in your bank account this Thursday....and then every Thursday after for as long as you own the stock! [Tap here to reveal the name of this stock for FREE.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Homology Medicines, FIXX]( Recent Analyst Action: Matthew Barcus, analyst at Chardan Capital, reiterates coverage on [Homology Medicines (FIXX)](in the Healthcare sector with a Buy rating and a price target of $8.00 (1 day ago). - Recent Price: $2.26 - Average Analyst Price Target: $10.40 (360.18%) - Market Cap: $117.26M [TipRanks.com]( also reports that [Homology Medicines](currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.40. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $3.00. [Homology Medicines (FIXX)](’s last closing price was $2.26 which would put the average price target at $10.40. Here are 3rd party ratings for [FIXX](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Sell, Top 23% (57 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Dada Nexus, DADA]( Recent Analyst Action: Andre Chang, analyst at J.P. Morgan, reiterates coverage on [Dada Nexus (DADA)](in the Industrial Goods sector with a Buy rating and a price target of $7.5 (1 day ago). - Recent Price: $5.32 - Average Analyst Price Target: $11.53 (116.73%) - Market Cap: $1.33B [TipRanks.com]( also reports that [Dada Nexus](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $11.53. The target pricing ranges from a high forecast of $19.00 down to a low forecast of $6.60. [Dada Nexus (DADA)](’s last closing price was $5.32 which would put the average price target at $11.53. Here are 3rd party ratings for [DADA](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 50% (125 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Millionaire Investor Reveals: "How I Made My Second Fortune... By Avoiding 99% of Stocks"]( [eb528704-62b...](Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market. [Revealed here: the name and ticker of the #1 stock.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Vigil Neuroscience Inc, VIGL]( Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on [Vigil Neuroscience Inc (VIGL)](in the Services sector with a Hold rating and a price target of $12.00 (3 days ago). - Recent Price: $13.05 - Average Analyst Price Target: $18.33 (40.46%) - Market Cap: $469.67M [TipRanks.com]( also reports that [Vigil Neuroscience Inc](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $18.33 . The target pricing ranges from a high forecast of $24.00 down to a low forecast of $12.00. [Vigil Neuroscience Inc (VIGL)](’s last closing price was $13.05 which would put the average price target at $18.33. Here are 3rd party ratings for [VIGL](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 24% (59 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Atento, ATTO]( Recent Analyst Action: Vincent Colicchio, analyst at Barrington, reiterates coverage on [Atento (ATTO)](in the Services sector with a Buy rating and a price target of $15.00 (2 days ago). - Recent Price: $4.45 - Average Analyst Price Target: $15.00 (237.08%) - Market Cap: $66.75M [TipRanks.com]( also reports that [Atento](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.00. The target pricing ranges from a high forecast of $15.00 down to a low forecast of $15.00. [Atento (ATTO)](’s last closing price was $4.45 which would put the average price target at $15.00. Here are 3rd party ratings for [ATTO](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 27% (69 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [How High Can Copper Go?]( [c822a1ed-f3f...](To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go? [Find Out in this Research Report.]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Allego, ALLG]( Recent Analyst Action: Gabriel Daoud, analyst at Cowen & Co., reiterates coverage on [Allego (ALLG)](in the Consumer Goods sector with a Buy rating and a price target of $4.00 (2 days ago). - Recent Price: $3.31 - Average Analyst Price Target: $7.00 (111.48%) - Market Cap: $889.70M [TipRanks.com]( also reports that [Allego](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.00. The target pricing ranges from a high forecast of $10.00 down to a low forecast of $4.00. [Allego (ALLG)](’s last closing price was $3.31 which would put the average price target at $7.00. Here are 3rd party ratings for [ALLG](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 47% (118 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Repay Holdings, RPAY]( Recent Analyst Action: Charles Nabhan, analyst at Stephens, reiterates coverage on [Repay Holdings (RPAY)](in the Services sector with a Buy rating and a price target of $9.00 (3 days ago). - Recent Price: $8.02 - Average Analyst Price Target: $9.83 (22.57%) - Market Cap: $1.47B [TipRanks.com]( also reports that [Repay Holdings](currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $9.83. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $7.50. [Repay Holdings (RPAY)](’s last closing price was $8.02 which would put the average price target at $9.83. Here are 3rd party ratings for [RPAY](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 48% (121 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [New "Vertical" Technology Solves Solar Power's Major Flaw]( [43705a26-d32...](Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive... Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power. [See How Early Stage Investors in This Solar Tech Could Benefit]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers acorss all US Exchanges. Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software